Volume 1.13 | Apr 16

Prostate Cell News 1.13, April 16, 2010.
In this issue: Science News  |  Current Publications  |  Industry News  |  Policy News  |  Events Subscribe  |  Unsubscribe


Prostate Cancer: Beta Control Your Hormones
Researchers describe a signaling pathway involving estrogen receptor beta (ERbeta) that governs whether prostate carcinoma cells maintain an epithelial phenotype or undergo epithelial-mesenchymal transition, suggesting that ERbeta would have prognostic or therapeutic value. [Cancer Cell]

Watch Procedure Now  
Use ALDEFLUOR® to Detect Prostate Precursor Cells
by STEMCELL Technologies


Prostate Cancer Linked to Increased Risk of Blood Clots
Scientists have found that men with prostate cancer are at increased risk of thromboembolism, particularly those receiving hormone therapy. [Press release from King’s College London discussing the online prepublication in the Lancet Oncology]

New Targeted Therapy Effective in Treating Advanced Prostate Cancer
An experimental drug is showing promise for the treatment of men with an aggressive form of advanced prostate cancer. [Press release from Memorial Sloan-Kettering Cancer Center discussing the online prepublication in Lancet]

Watch Procedure Now  
Optimized Enzymes and Protocols for
Prostate Tissue Dissociation

by STEMCELL Technologies



ER(Beta) Impedes Prostate Cancer EMT by Destabilizing HIF-1(Alpha) and Inhibiting VEGF-Mediated Snail Nuclear Localization: Implications for Gleason Grading
Researchers report that a key function of ER(beta) and its specific ligand 5(alpha)-androstane-3(beta),17(beta)-diol [3(beta)-adiol] is to maintain an epithelial phenotype and repress mesenchymal characteristics in prostate carcinoma. [Cancer Cell]

Immunohistochemical Expression of BRCA1 and Lethal Prostate Cancer
Researchers hypothesized that BRCA1 expression in prostate tumor tissue may be associated with prostate cancer progression through regulation of the cell cycle. [Cancer Res]

ID1 Enhances Docetaxel Cytotoxicity in Prostate Cancer Cells through Inhibition of p21
To identify potential mechanisms underlying prostate cancer chemotherapy response and resistance, researchers compared the gene expression profiles in high-risk human prostate cancer specimens before and after neoadjuvant chemotherapy and radical prostatectomy. [Cancer Res]

Human Carboxypeptidase A4: Characterization of the Substrate Specificity and Implications for a Role in Extracellular Peptide Processing
In the present study, researchers determined that carboxypeptidase A4 is secreted from cells as a soluble proenzyme that can be activated by endoproteases such as trypsin. [J Biol Chem]

Aberrant Activation of the Androgen Receptor by NF-(Kappa)B2/p52 in Prostate Cancer Cells
In the present study, researchers showed that NF-(kappa)B/p52 can activate the androgen receptor (AR), resulting in increased transactivation of AR-responsive genes, such as PSA and NKX3.1, in a ligand-independent manner. [Biochemistry]

Usefulness of the Top-Scoring Pairs of Genes for Prediction of Prostate Cancer Progression
The top-scoring pair approach can be used to identify patients whose prostate cancer will progress after they undergo radical prostatectomy. Two gene pairs can predict which men would experience progression to the metastatic form of the disease. [Prostate Cancer Prostatic Dis]

MicroRNA Let-7a Inhibits Proliferation of Human Prostate Cancer Cells In Vitro and In Vivo by Targeting E2F2 and CCND2
In this study, researchers used in vitro and in vivo approaches to investigate whether E2F2 and CCND2 are direct targets of let-7a, and if let-7a acts as a tumor suppressor in prostate cancer by down-regulating E2F2 and CCND2. [PLoS ONE]


Risk of Thromboembolic Diseases in Men with Prostate Cancer:  Results from the Population-Based PCBaSe Sweden
Researchers investigated the risk of thromboembolic disease in men with prostate cancer who were receiving endocrine treatment, curative treatment, or surveillance. [Lancet Oncol]

Antitumour Activity of MDV3100 in Castration-Resistant Prostate Cancer: A Phase I-II Study
Because growth of castration-resistant prostate cancer is dependent on continued androgen-receptor signalling, researchers assessed the antitumour activity and safety of MDV3100 in men with this disease. [Lancet]


Approval Closer for Old Stem Cell Lines
WiCell, a nonprofit at the University of Wisconsin, asked the National Institutes of Health to add four lines to the agency’s registry of cells that can be studied with federal funds. [ScienceInsider]

Pfizer Enters Reagent Partnership with Stemgent
Pfizer Inc. said it will partner with reagent maker Stemgent Inc. to make new reagents available to researchers. [BusinessWeek]

Circadian’s VGX-100 Significantly Inhibits Tumour Growth in Animal Models of Human Cancer
Treatment with VGX-100 plus anti-cancer drug Avastin and chemotherapy (docetaxel) significantly inhibited tumour growth and extended life-expectancy in mouse models of human prostate cancer above the effect seen with Avastin plus docetaxel alone. [The Wall Street Journal]


University of Chicago Physician Named to Presidential Commission for the Study of Bioethical Issues
Daniel Sulmasy, MD, PhD, the Kilbride-Clinton Professor of Medicine and Ethics in the Department of Medicine and the Divinity School, and Associate Director of the MacLean Center for Clinical Medical Ethics at the University of Chicago, has been named to the Presidential Commission for the Study of Bioethical Issues. [Presidential Commission for the Study of Bioethical Issues, United States]

National Human Genome Research Institute Names New Chief of Genome Technology Branch
The National Human Genome Research Institute (NHGRI), part of the National Institutes of Health, has named Lawrence C. Brody, Ph.D., as the new chief of its Genome Technology Branch, the largest of seven branches in the NHGRI Division of Intramural Research. [National Institutes of Health, United States]

Minor Use Minor Species Development of Drugs; Research Project Grant (R01) (RFA-FD-10-001) [National Institutes of Health, United States]

Bioengineering Nanotechnology Initiative [STTR (R41/R42)] (PA-10-149) [National Institutes of Health, United States]

Bioengineering Nanotechnology Initiative [SBIR (R43/R44)] (PA-10-150) [National Institutes of Health, United States]

Clinical Investigator Status (Biologics) [Food and Drug Administration, United States]

Background on Study Results of U.S. Academic Researchers [Food and Drug Administration, United States]

Secretary Sebelius Announces Five New Health and Human Services Regional Directors [Department of Health & Human Services, United States]


American Association for Cancer Research (AACR) 101st Annual Meeting
April 17-21, 2010
Washington, DC, United States

American Urological Association (AUA) 2010 Annual Meeting
May 29-June 3, 2010
San Francisco, United States

International Society for Stem Cell Research (ISSCR) 8th Annual Meeting
June 16-19, 2010
San Francisco, United States

21st Meeting of the European Association for Cancer Research (EACR) 
June 26-29, 2010
Oslo, Norway

United Kingdom National Stem Cell Network (UKNSCN) Third Annual Scientific Conference
July 12-14, 2010
Nottingham, United Kingdom

2010 World Cancer Congress
August 18-21, 2010
Shenzhen, China

Joint Annual Meeting of the International Continence Society (ICS) and International Urogynecological Association (IUGA)
August 23-27, 2010
Toronto, Canada

28th World Congress of Endourology and SWL
September 1-4, 2010
Chicago, United States

35th European Society for Medical Oncology (ESMO) Congress
October 8-12, 2010
Milan, Italy

Visit our events page to stay up to date with the latest events in the cell, gene and immunotherapy community.


Sr. Product Support and Training Specialist (CardianBCT)

Recruit Top Talent

Reach more than 11,000 potential candidates by posting your organization’s career opportunities with Cell Therapy News.
Visit here to post your career opportunities.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Learn more about Prostate Cell News: Archives  |  Events  |  Subscribe  |  Contact Us